|
Correlation of PIK3CA mutations in cell-free DNA (cfDNA) and efficacy of everolimus (EVE) in metastatic breast cancer: Results from BOLERO-2. |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Francois Philippe Ringeisen |
|
|
|
Consulting or Advisory Role - Antigen Express; Bayer; Celgene; Lilly; Merck; Metastat; Novartis; Peregrine Pharmaceuticals; Pfizer |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Oncothyreon; Takeda |
Research Funding - Lilly (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bayer; GlaxoSmithKline; Takeda |